{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:04Z","timestamp":1761920464262,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":379,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.5604\/01.3001.0011.7388","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T06:25:00Z","timestamp":1525847100000},"page":"437-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience"],"prefix":"10.1016","volume":"17","author":[{"given":"Bandar","family":"Al-Judaibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Benmassaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Katherine","family":"Dokus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trana","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bilodeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly W.","family":"Burak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric. M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0011.7388_bib0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/01.3001.0011.7388_bib0010","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/liv.12599","article-title":"Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity","volume":"34","author":"Asselah","year":"2014","journal-title":"Liver Int"},{"key":"10.5604\/01.3001.0011.7388_bib0015","unstructured":"Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/ fs164\/en\/2017. September 01, 2017."},{"key":"10.5604\/01.3001.0011.7388_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/1319-3767.170947","article-title":"The new era of hepatitis C virus therapy","volume":"21","author":"Al-Judaibi","year":"2015","journal-title":"Saudi J Gastroenterol"},{"key":"10.5604\/01.3001.0011.7388_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/1319-3767.118133","article-title":"Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review","volume":"19","author":"Wells","year":"2013","journal-title":"Saudi J Gastroenterol"},{"key":"10.5604\/01.3001.0011.7388_bib0030","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2011.03899.x","article-title":"Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN\/UNOS data","volume":"12","author":"Uemura","year":"2012","journal-title":"Am J Transplant"},{"issue":"Suppl. 1","key":"10.5604\/01.3001.0011.7388_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.5604\/01.3001.0011.7388_bib0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1155\/2014\/317623","article-title":"Burden of disease and cost of chronic hepatitis C infection in Canada","volume":"28","author":"Myers","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.5604\/01.3001.0011.7388_bib0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","volume":"60","author":"Coilly","year":"2014","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0011.7388_bib0050","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14218\/JCTH.2013.00002","article-title":"Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances","volume":"2","author":"Bunchorntavakul","year":"2014","journal-title":"J Clin Transl Hepatol"},{"key":"10.5604\/01.3001.0011.7388_bib0060","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1600-6143.2009.02702.x","article-title":"A practical guide to the management of HCV infection following liver transplantation","volume":"9","author":"Watt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.5604\/01.3001.0011.7388_bib0065","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"11","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.5604\/01.3001.0011.7388_bib0070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.5604\/01.3001.0011.7388_bib0075","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.5604\/01.3001.0011.7388_bib0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0168-8278(15)30009-X","article-title":"Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with\/without ribavirin is effective in HCV Genotypes 1 and 3","volume":"62","author":"Foster","year":"2015","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0011.7388_bib0085","first-page":"227","article-title":"SVR12 results from the Phase II, open-label IMPACT study of simeprevir in combination with daclatasvir and sofosbuvir in treatment- naive and -experienced patients with chronic HCV genotype 1\/4 infection and decompensated liver disease","volume":"62","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0090","first-page":"311","article-title":"Curing decompensated wait listed HCV patients with the new DAAs: the potential significant impact on liver transplant wait list and organ allocation","volume":"62","author":"Munoz","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0095","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.28923","article-title":"Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy","volume":"65","author":"Flemming","year":"2017","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29054","article-title":"The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy","volume":"65","author":"Verna","year":"2017","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0110","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/lt.500040401","article-title":"Cholestatic hepatitis C in liver allografts","volume":"4","author":"Taga","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"10.5604\/01.3001.0011.7388_bib0125","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transpl"},{"key":"10.5604\/01.3001.0011.7388_bib0130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ctr.12596","article-title":"A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation","volume":"29","author":"Barsa","year":"2015","journal-title":"Clin Transplant"},{"key":"10.5604\/01.3001.0011.7388_bib0135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.5604\/01.3001.0011.7388_bib0140","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0011.7388_bib0145","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.27937","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis","volume":"62","author":"Aqel","year":"2015","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/01.3001.0011.7388_bib0155","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0160","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/jvh.12645","article-title":"Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease","volume":"24","author":"Lawitz","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.5604\/01.3001.0011.7388_bib0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0011.7388_bib0170","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.28926","article-title":"Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list","volume":"65","author":"Chhatwal","year":"2017","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0011.7388_bib0175","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13798","article-title":"Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis","volume":"44","author":"Njei","year":"2016","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119301991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119301991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:37:16Z","timestamp":1761647836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119301991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1665268119301991"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0011.7388","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0011.7388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}